Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:20 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours
NCT04949425 · AstraZeneca · PHASE1 · terminated · last registry update 2022-09-02 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study terminated because the clinical development programme for Adavosertib has been discontinued” | – | Registry record, AstraZeneca |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against WEE1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-08-14Results posted on the registry: AstraZeneca, Adavosertib (NCT04590248)
- 2023-06-06Results posted on the registry: National Cancer Institute (NCI), Adavosertib + Cisplatin (NCT03345784)
- 2023-04-25Results posted on the registry: National Cancer Institute (NCI), AZD1775 + Gemcitabine (NCT02194829)
- 2022-12-28Results posted on the registry: Joseph Paul Eder, AZD2281 + AZD5363 (NCT02576444)
- 2022-12-28Also stopped (terminated): Joseph Paul Eder, AZD2281 + AZD5363 (NCT02576444)
- 2022-10-05Results posted on the registry: National Cancer Institute (NCI), Adavosertib + Irinotecan Hydrochloride (NCT02095132)
- 2022-09-16Also stopped (terminated): AstraZeneca, Adavosertib + Itraconazole (NCT04959266)
- 2022-09-06Also stopped (terminated): AstraZeneca, [14C]Adavosertib (NCT05008913)
- 2022-06-14Also stopped (withdrawn): James Cleary, MD, PhD, Adavosertib + Gemcitabine (NCT05212025)
- 2022-05-10Results posted on the registry: National Cancer Institute (NCI), Adavosertib + Carboplatin (NCT01827384)
- 2022-03-22Results posted on the registry: AstraZeneca, Olaparib Continuous (28-Day cycle) 300 mg BD. + Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle). (NCT03330847)
- 2021-11-23Results posted on the registry: Dana-Farber Cancer Institute, Cisplatin + AZD1775 (NCT03012477)
- 2021-09-09Results posted on the registry: AstraZeneca, Durvalumab and Tremelimumab + AZD1775 and carboplatin (CBPT) (NCT02937818)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision